HC Wainwright Estimates Biomea Fusion Q1 Earnings

Biomea Fusion, Inc. (NASDAQ:BMEA) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Biomea Fusion in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.12) per share for the quarter. The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($0.78) EPS.

Several other equities analysts also recently weighed in on the stock. Rodman & Renshaw assumed coverage on shares of Biomea Fusion in a report on Tuesday, January 13th. They set a “buy” rating and a $8.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Biomea Fusion in a research note on Wednesday, January 21st. Finally, D. Boral Capital restated a “buy” rating and set a $12.00 target price on shares of Biomea Fusion in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.63.

Biomea Fusion Trading Up 12.3%

Biomea Fusion stock opened at $1.37 on Friday. Biomea Fusion has a 12-month low of $0.87 and a 12-month high of $3.08. The firm has a market capitalization of $99.05 million, a price-to-earnings ratio of -1.05 and a beta of -0.20. The firm has a 50 day moving average of $1.29 and a 200 day moving average of $1.43.

Institutional Trading of Biomea Fusion

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its stake in Biomea Fusion by 670.5% in the 1st quarter. AQR Capital Management LLC now owns 264,028 shares of the company’s stock worth $562,000 after purchasing an additional 229,763 shares during the period. XTX Topco Ltd bought a new stake in shares of Biomea Fusion during the second quarter valued at approximately $270,000. Scotia Capital Inc. bought a new stake in shares of Biomea Fusion during the second quarter valued at approximately $459,000. Aisling Capital Management LP lifted its holdings in shares of Biomea Fusion by 156.5% in the second quarter. Aisling Capital Management LP now owns 2,048,757 shares of the company’s stock worth $3,688,000 after buying an additional 1,250,000 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its holdings in shares of Biomea Fusion by 99.2% in the second quarter. Bridgeway Capital Management LLC now owns 70,300 shares of the company’s stock worth $127,000 after buying an additional 35,000 shares in the last quarter. Institutional investors own 96.72% of the company’s stock.

About Biomea Fusion

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.